Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reinventing biotech systems for patient impact.

Nature medicine·2026
Same author

Follow the data: tracking data quality and completeness in oncology real-world data.

JAMIA open·2026
Same author

Physical Activity and Stroke Incidence among Postmenopausal Women: Insights from the Women's Health Initiative.

Neuroepidemiology·2025
Same author

Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence.

Clinical therapeutics·2025
Same author

Addressing the challenges of integrating digital health technologies to measure patient-centred outcomes in clinical registries.

The Lancet. Digital health·2024
Same author

Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.

JAMA·2024

Related Experiment Video

Updated: May 18, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

A framework for understanding cancer comparative effectiveness research data needs.

William R Carpenter1, Anne-Marie Meyer, Amy P Abernethy

  • 1Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA. wrc4@email.unc.edu

Journal of Clinical Epidemiology
|September 29, 2012
PubMed
Summary
This summary is machine-generated.

A new patient-centered model improves cancer comparative effectiveness research by reflecting real-world care. This enhances data systems for better clinical decision-making and policy.

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Related Experiment Videos

Last Updated: May 18, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Area of Science:

  • Oncology
  • Health Services Research
  • Data Science

Background:

  • Randomized controlled trials (RCTs) are standard but have limitations in reflecting patient diversity and real-world practice.
  • Comparative effectiveness research (CER) uses secondary data to address RCT gaps but has its own challenges.
  • Existing models may not fully capture the complexities of contemporary cancer care.

Purpose of the Study:

  • To develop a novel model for cancer comparative effectiveness research.
  • To inform an evolving framework for cancer CER data requirements.
  • To better align research with clinical practice and stakeholder needs.

Main Methods:

  • Examination of existing models in cancer CER.
  • Conducting semi-structured discussions with 76 clinicians and researchers.
  • Iterative development of a new conceptual model.

Main Results:

  • A new patient-centered, longitudinal chronic care model was developed.
  • The model better represents the cancer care continuum than an acute-care perspective.
  • Identified key data needs for enhancing cancer CER.

Conclusions:

  • The developed model is immediately relevant for federally funded CER programs.
  • It informs an evolving framework for cancer CER data needs, including registries and epidemiologic systems.
  • Addresses contemporary clinical practice, methodological improvements, and stakeholder needs for actionable findings.